首页> 外文期刊>Japanese Journal of Cancer Research >Multidrug resistance phenotype in the RMS-GR human rhabdomyosarcoma cell line obtained after polychemotherapy.
【24h】

Multidrug resistance phenotype in the RMS-GR human rhabdomyosarcoma cell line obtained after polychemotherapy.

机译:多化学疗法后获得的RMS-GR人横纹肌肉瘤细胞系中的多药耐药表型。

获取原文
获取原文并翻译 | 示例
           

摘要

Classical cytotoxic treatment of rhabdomyosarcoma (RMS), the most common soft tissue malignacy in children, is often accompanied by significant morbidity and poor response. Chemotherapy may induce multidrug resistance (MDR) associated with the expression of P-glycoprotein, a drug efflux pump which modifies the sensitivity of tumoral cells to drugs. To analyze MDR in RMS we used the RMS-GR cell line, obtained from an embryonal rhabdomyosarcoma treated in vivo with polychemotherapy. The RMS-GR cells showed cross-resistance to vincristine, doxorubicin and actinomycin D, the drugs of choice in the conventional treatment of RMS. Polymerase chain reaction (PCR) analysis showed that these RMS cells overexpressed mdr1/P-glycoprotein. The pattern of resistance and the level of P-glycoprotein expression were similar to those found in the resistant RMS TE.32.7.DAC cell line obtained in vitro. Southern blot analysis showed that mdr1 overexpression was not due to amplification of the gene. Our results showed that the in vivo treatment of embryonal RMS may induce an MDR phenotype mediated by mdr1/P-glycoprotein in RMS cells.
机译:横纹肌肉瘤(RMS)是儿童中最常见的软组织恶性肿瘤的经典细胞毒性治疗方法,通常伴有明显的发病率和不良反应。化学疗法可能诱导与P-糖蛋白表达相关的多药耐药性(MDR),P-糖蛋白是一种药物外排泵,可改变肿瘤细胞对药物的敏感性。为了分析RMS中的MDR,我们使用了RMS-GR细胞系,该细胞系得自通过多化学疗法体内治疗的胚胎性横纹肌肉瘤。 RMS-GR细胞对长春新碱,阿霉素和放线菌素D(在RMS常规治疗中选择的药物)具有交叉耐药性。聚合酶链反应(PCR)分析表明,这些RMS细胞过表达了mdr1 / P-糖蛋白。耐药模式和P-糖蛋白表达水平与体外获得的耐药RMS TE.32.7.DAC细胞系相似。 Southern印迹分析表明mdr1过表达不是由于基因的扩增。我们的结果表明,胚胎RMS的体内治疗可能诱导RMS细胞中由mdr1 / P-糖蛋白介导的MDR表型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号